VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.
Metrics to compare | VNRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVNRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.0x | −3.8x | −0.5x | |
PEG Ratio | −0.08 | −0.21 | 0.00 | |
Price/Book | −2.2x | 2.9x | 2.6x | |
Price / LTM Sales | 53.8x | 3.7x | 3.3x | |
Upside (Analyst Target) | 316.7% | 18.2% | 38.7% | |
Fair Value Upside | Unlock | −4.7% | 5.0% | Unlock |